DE60120458D1 - Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen - Google Patents

Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen

Info

Publication number
DE60120458D1
DE60120458D1 DE60120458T DE60120458T DE60120458D1 DE 60120458 D1 DE60120458 D1 DE 60120458D1 DE 60120458 T DE60120458 T DE 60120458T DE 60120458 T DE60120458 T DE 60120458T DE 60120458 D1 DE60120458 D1 DE 60120458D1
Authority
DE
Germany
Prior art keywords
vitamin
compounds
determining
initial dose
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60120458T
Other languages
English (en)
Other versions
DE60120458T2 (de
Inventor
J Amdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE60120458D1 publication Critical patent/DE60120458D1/de
Application granted granted Critical
Publication of DE60120458T2 publication Critical patent/DE60120458T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60120458T 2000-10-13 2001-10-12 Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen Expired - Fee Related DE60120458T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24012600P 2000-10-13 2000-10-13
US240126P 2000-10-13
PCT/US2001/042708 WO2002031514A2 (en) 2000-10-13 2001-10-12 A method of determining the initial dose of vitamin d compounds

Publications (2)

Publication Number Publication Date
DE60120458D1 true DE60120458D1 (de) 2006-07-20
DE60120458T2 DE60120458T2 (de) 2007-01-11

Family

ID=22905214

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120458T Expired - Fee Related DE60120458T2 (de) 2000-10-13 2001-10-12 Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen

Country Status (12)

Country Link
US (1) US20030092686A1 (de)
EP (1) EP1334367B1 (de)
JP (1) JP2004532801A (de)
AT (1) ATE329268T1 (de)
AU (2) AU1348302A (de)
CA (1) CA2423316A1 (de)
CY (1) CY1106146T1 (de)
DE (1) DE60120458T2 (de)
DK (1) DK1334367T3 (de)
ES (1) ES2266276T3 (de)
PT (1) PT1334367E (de)
WO (1) WO2002031514A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6066091A (en) * 1998-02-23 2000-05-23 North Carolina State University Methods, systems and products for determining drug withdrawal intervals

Also Published As

Publication number Publication date
CY1106146T1 (el) 2011-06-08
AU2002213483B2 (en) 2007-03-29
ATE329268T1 (de) 2006-06-15
AU1348302A (en) 2002-04-22
WO2002031514A3 (en) 2003-06-05
EP1334367B1 (de) 2006-06-07
WO2002031514A2 (en) 2002-04-18
DK1334367T3 (da) 2006-10-09
EP1334367A2 (de) 2003-08-13
CA2423316A1 (en) 2002-04-18
PT1334367E (pt) 2006-10-31
JP2004532801A (ja) 2004-10-28
US20030092686A1 (en) 2003-05-15
ES2266276T3 (es) 2007-03-01
DE60120458T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
WO2001027119A3 (de) Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
FI904450A0 (fi) Nya peptidas- och isomerasinhibitorer.
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE10197144T1 (de) Verfahren zur Herstellung von Nitrilverbindungen aus ethylenisch ungesättigten Verbindungen
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
ATE268749T1 (de) Verfahren zur herstellung von iopamidol
RU92004530A (ru) Производные гуанидиналкил-1,1-бис-фосфоновой кислоты, способ их получения, лекарственные средства и способ их получения
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE69907258D1 (de) Verfahren zur herstellung von dinatriumpamidronat
DE59600209D1 (de) Verfahren zur Herstellung von 4,6-Dichlorpyrimidinen
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
ATE329268T1 (de) Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
DK0752991T3 (da) Indeno[1,2-e]pyrazin-4-oner, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
ATE270275T1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE111734T1 (de) Verfahren zur herstellung von direktkomprimierten, cephalosporansäure derivate enthaltendentabletten.
NZ519722A (en) Treatment of diabetic ulcers
IS4392A (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
DK0614366T3 (da) Anvendelse af creatinphosphat eller phosphoenolpyrodruesyre til behandling af tumorer
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
DE60104535D1 (de) Verfahren zur hydroxylation von aliphatischen verbindungen
DE59300386D1 (de) Verfahren zur Herstellung von Siliciumnitrid, Ausgangsverbindung hierfür sowie Verfahren zu dessen Herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee